Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000899243-19-017480
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-06-19 18:52:17
Reporting Period:
2019-06-17
Accepted Time:
2019-06-19 18:52:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1740547 Urovant Sciences Ltd. UROV () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1290166 Qvt Associates Gp Llc 444 Madison Avenue, 21St Floor
New York NY 10022
No No Yes No
1771138 Ltd. Cayman Investment Financial Qvt 190 Elgin Avenue
George Town, Grand Cayman E9 KY1-9005
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares, Par Value $0.000037453 Per Share Acquisiton 2019-06-17 6,541 $8.53 22,848,350 No 4 P Indirect (see fn5)
Common Shares, Par Value $0.000037453 Per Share Acquisiton 2019-06-18 6,706 $8.21 22,855,056 No 4 P Indirect (see fn5)
Common Shares, Par Value $0.000037453 Per Share Acquisiton 2019-06-19 4,957 $8.17 22,860,013 No 4 P Indirect (see fn5)
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect (see fn5)
No 4 P Indirect (see fn5)
No 4 P Indirect (see fn5)
Footnotes
  1. The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act.
  2. The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.11 to $8.70, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.09 to $8.29, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.00 to $8.27, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4.
  5. QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,860,013 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.